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Background: Numerous studies have explored the correlation of periodontal disease (PD) with risk of hematopoi-
etic and lymphatic cancers, but the findings were inconsistent. Therefore, we did a meta-analysis to ascertain the 
correlation of PD with risk of incident hematopoietic and lymphatic cancers. 
Material and Methods: The authors searched relevant studies in databases (PubMed, Web of Science, and MED-
LINE). The summary relative risk (RR) along with 95% confidence interval (CI) was calculated by use of random 
or fixed effects models. 
Results: Six studies were included in qualitative synthesis. The pooled analysis revealed that PD was significantly 
associated with an increased risk of hematopoietic and lymphatic cancers (RR = 1.17; 95% CI = 1.07–1.27; P = 0). 
Stratified analysis showed the association of PD with hematopoietic and lymphatic cancers remained significant in 
the never smokers (RR = 1.28; 95% CI = 1.07–1.54; P = 0.007), and in the American population (RR = 1.17; 95% 
CI = 1.05–1.30; P = 0.003), respectively.
Conclusion: Never smokers population and the American population with PD have a higher risk of developing 
hematopoietic and lymphatic cancers. PD might be considered as a risk factor for hematopoietic and lymphatic 
cancers.  
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Introduction
PD is a chronic inflammatory condition that affects the 
tissues surrounding the teeth, including alveolar bone, 
cementum, periodontal ligament and gingival. If peri-
odontitis remains untreated, it may lead to annihila-
tion of periodontium, tooth looseness and ultimately 
tooth loss. PD has been reported to increase the risk of 
chronic diseases, such as diabetes, cardiovascular dis-
ease, rheumatoid arthritis, and pulmonary disease (1-5). 
Furthermore, increasing evidence indicates that people 
with periodontitis may be at higher risk of developing 
oral cancers (6), cancer of head and neck (7-8), esoph-
agus (9), lung (4), pancreas (10), colorectum (11), and 
breast (12). Additionally, greater number of tooth loss 
might increase the risk of developing cancer in patients.
Hematopoietic and lymphatic malignancies are cancers 
that affect blood, lymphatic system, and bone marrow. 
There are a number of risk factors associated with lym-
phoma (Hodgkin lymphoma, non-Hodgkin lymphoma), 
such as age, gender, Epstein-Barr infection, and im-
mune dysregulation (https://www.cancer.gov/types/
lymphoma). The most common risk factors associated 
with hematopoietic cancers (acute lymphoblastic leuke-
mia, acute myelogenous leukemia, chronic lymphocytic 
leukemia, chronic myelogenous leukemia, multiple my-
eloma) include older age, smoking, prior chemotherapy, 
and exposure to radiation (https://www.cancer.gov/
types/leukemia). 
Recently, numerous epidemiological studies exploring 
the risk of hematopoietic and lymphatic cancers in pa-
tients with periodontitis have been published (13-19). 
However, these studies showed inconsistent results and 
the evidence remained inclusive. Therefore, we aimed 
to systematically evaluate the published literature and 
to quantify the association of periodontitis with risk of 
hematopoietic and lymphatic cancers via meta-analysis.
Material and Methods
-  Literature and search strategy
We followed the instructions of the PRISMA to con-
duct this meta-analysis (20). The focused question fol-
lowed the PECO (population, exposure, comparison, 
outcomes) criteria: The population (P) was patients of 
any age; the exposure (E) was the presence of periodon-
tal diseases (PDs); the comparison (C) was the absence 
of PDs; and the outcomes (O) were patients diagnosed 
with hematopoietic or lymphatic cancers.
PubMed, Web of Science, and MEDLINE were system-
atically searched to identify potentially eligible studies 
that assessed the correlation of PDs with hematopoi-
etic and lymphatic cancers. We used the search terms: 
(“periodontal diseases” or periodontitis or gingivitis or 
“tooth loss” or “teeth loss”) and (hematological or hae-
matological or hematologic or hematopoietic or lym-
phatic or lymphomas or lymphoma or lymphoid) and 
(cancers or malignancies). The search was completed on 
31 Oct 2018. 
-  Selection criteria, data extraction and quality assessment
Published studies that estimated the relative risk of 
hematopoietic and lymphatic cancers associated with 
any measure of PD (i.e. periodontitis, gingivitis) were 
eligible. Comments, review articles and meta-analysis 
were excluded.
The following data from each included study were 
independently extracted by two investigators (YGW 
and XJS). The relevant data included first author of 
the study, year of publication, country of origin, study 
design, sample sizes in each group, age, gender, can-
cer type, duration of follow-up, exposure, relative risk 
(RR), hazards ratios (HR), or odds ratio (OR) estimates 
with 95%CI for outcomes. 
The quality of included studies was assessed according 
to the Newcastle-Ottawa Scale (NOS) (21). This scale 
consists of assessment of three parts: selection (0-4 
points), comparability (0-2 points), and outcome/expo-
sure (0-3 points) for a total score of 9 points. In the NOS, 
poor, moderate, and high quality was scored 0–3, 4–6, 
and 7–9, respectively.
-  Statistical analysis
Relative risk (RR) with 95% confidence interval (CI) 
was used as the common measure of association across 
studies. RR was calculated by the formula RR = (event/
total)exposure/(event/total)non-exposure, in which (event/total)
exposure and (event/total)non-exposure is the incidence of an 
outcome of interest in the exposed group and non-ex-
posed group, respectively. HR was considered equiva-
lent to RR when pooled in qualitative synthesis. When 
the incidence of outcome is more than 10% in a cohort 
study, the OR was transformed into RR with this for-
mula: RR = OR/[(1 – P0) + (P0 × OR)], in which P0 is the 
incidence of the outcome of interest in the non-exposed 
group (22). The standard error (SE) of the converted 
RR was determined with this formula: SElog(RR) = 
SElog(OR) × log(RR)/log(OR) (23). 
Heterogeneity across studies was evaluated using the Q 
statistic (P < 0.10 was regarded as statistical significance) 
and was quantified with I2 statistic. I2 values higher than 
50% indicated moderate heterogeneity. In the presence 
of heterogeneity (P < 0.10), we combined the effect es-
timates across studies by use of a random-effects model 
(24); otherwise, the fixed effect model was adopted (25). 
The potential heterogeneity across studies was explored 
by subgroup analysis and sensitivity analysis. Sensitiv-
ity analysis was conducted via deleting each study at 
a time and calculating the summary effect size of the 
remaining studies. The funnel plots as well as Egger 
regression test were applied to assess publication bias 
(26). We used STATA 14.0 (Stata Corporation, College 
Station, TX, U.S.A.) for data analysis. Two-sided P < 
0.05 was regarded as statistically significant.
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Results
-  Literature retrieved and study characteristics
A total of 853 articles were initially identified and as-
sessed. Fig. 1 showed the detailed flow diagram of 
the exclusion and inclusion process. Two articles used 
the same dataset so the more comprehensive analysis 
by Bertrand et al. (16) was included and the study by 
Michaud et al. (27) was excluded from the quantitative 
synthesis. The study by Dizdar et al. was excluded for 
poor quality. The study by WEN et al. (28) was also 
excluded because of ineligible comparator. Six articles 
ultimately were eligible for inclusion and were included 
in qualitative synthesis (13-18). Five of the six studies 
were cohort studies (14-18), and one study (13) was 
case-control study.
Table 1 summarized the detailed characteristics of in-
cluded studies reporting risk estimates for the correla-
tion of PD with hematopoietic and lymphatic cancers. 
Quality assessment of the included studies according to 
the NOS is shown in Table 2 and Table 3. All of the six 
















































no gingivitis and 
periodontitis
OR: 0.6 (0.2, 2.0) 
Converted RR: 
0.65 (0.21, 2.06)
















































HR: 0.72 (0.23, 2.26) Age and smoking
11/357 5/315
Severe peri-
odontitis vs. no 
periodontitis
HR: 2.09 (0.68, 6.47)
Age and 
smoking
19/1022 5/315 Periodontitis vs. no periodontitis RR: 1.17 (0.44, 3.10)
Bertrand  






















47/2249 298/19326 HRa: 1.16 (0.83, 1.61)
123/3973 363/16233 HRb: 1.31 (1.05, 1.63)
14/1274 30/3479 HRc: 2.59 (1.05, 6.35)










Table 1: Characteristics of studies on the association of periodontal disease with hematopoietic and lymphatic cancers.
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HR: 1.11 (0.95, 1.30) Age, smoking and BMI
112/7245 307/26852 HRa: 1.34 (1.08, 1.67)
Age and BMI111/8811 268/20200 HRb: 0.96 (0.77, 1.19)





HR: 1.08 (0.87, 1.34) Age, smoking and BMI
36/17103 105/48766 Multiple myeloma HR: 1.05 (0.72, 1.54)
Age, smoking 
and BMI
66/17103 168/48766 Leukemia HR: 1.10 (0.83, 1.47) Age, smoking and BMI
Michaud 
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odontitis









odontitis vs. no 
periodontitis
HR: 0.77 (0.49, 1.22)
24/1122 36/1710
Severe peri-
odontitis vs. no 
periodontitis
HR: 0.89 (0.52, 1.52)
18/1410 36/1710 Edentulism vs. no periodontitis HR: 0.61 (0.33, 1.12)
75/4346 36/1710 Periodontitis vs. no periodontitis RR: 0.82 (0.56, 1.22)
61/3625 26/1228 Periodontitis vs. no periodontitis RR
d: 0.80 (0.51, 1.26)
14/721 10/484 Periodontitis vs. no periodontitis RR
e: 0.94 (0.42, 2.10)
Abbreviations: OR, odds ratios; RR, relative risk; HR, hazard ratio; BMI, body mass index.
aNever smokers, bPast smokers, cCurrent smokers, dWhite, eNon-White.










































































Chung et al.  
(14) * * - - * * * * * 7
Mai  et al.  
(15) * * * * * - * * * 8
Bertrand  et 
al.  
(16)
* * - * * * * * * 8
Nwizu et al.  




* * * * * * * * * 9
Asterisk means that the item is satisfied.
Table 2: Quality assessment of cohort studies according to the Newcastle-Ottawa scale.
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* * * * * * - * - 7
Asterisk means that the item is satisfied.
Table 3: Quality assessment of case-control studies according to the Newcastle-Ottawa scale.
-  Overall estimates and subgroup analysis
Pooled results showed that subjects with PD have an in-
creased risk for hematopoietic and lymphatic cancers 
(RR = 1.17; 95 % CI 1.07–1.27; P = 0). No evidence of 
heterogeneity was observed (P = 0.263; I2 = 22.7%; Fig. 
2). Table 4 showed the results of subgroup analysis by 
study type, study design, smoking status, gender, coun-
try origin, ethnicity, and stage of PD. Results of the 
subgroup analyses based on cancer types indicated that 
patients with PD increased the risk of lymphatic can-
cers (RR = 1.21; 95% CI = 1.07–1.37), while the risk of 
hematopoietic cancers was not significant (RR = 1.08; 
95% CI = 0.86–1.36). Subgroup analyses according to 
study design revealed significant relation of PD with in-
creased risk of hematopoietic and lymphatic cancers in 
prospective cohort studies (RR = 1.17; 95% CI = 1.05–
1.30) and in retrospective studies (RR = 1.17; 95% CI = 
1.01–1.35).
Subgroup analyses No. of studies RR (95%CI) p P of heterogeneity I
2(%)
Overall 6 1.17 (1.07, 1.27) 0 0.263 22.7%
 Cancer types
Hematopoietic cancers 2 1.08 (0.86, 1.36) 0.501 0.848 0.0%
Lymphatic cancers 3 1.21 (1.07, 1.37) 0.002 0.219 34.1%
Study design
Prospective cohort 4 1.17 (1.05, 1.30) 0.003 0.143 44.8%
Retrospective cohort or  
case-control 2 1.17 (1.01, 1.35) 0.037 0.31 3.0%
Smoking status
Never smokers 2 1.28 (1.07, 1.54) 0.007 0.476 0.0%
Past smokers 2 1.12 (0.83, 1.52) 0.463 0.049 74.2%
Current smokers 2 1.25 (0.30, 5.25) 0.758 0.027 79.6%
Gender
Male and female 3 1.12 (0.98, 1.28) 0.109 0.148 47.6%
Female 2 1.11 (0.95, 1.30) 0.181 0.917 0.0%
Male 1 1.30 (1.11, 1.52) 0.001 NA NA
Country origin
Asia 1 1.18 (1.02, 1.37) 0.028 NA NA
USA 4 1.17 (1.05, 1.30) 0.003 0.143 44.8%
Europe 1 0.65 (0.21, 2.04) 0.46 NA NA
Ethnicity
White 2 1.07 (0.67, 1.68) 0.788 0.054 73.1%
Non-White 2 0.88 (0.48, 1.64) 0.698 0.817 0.0%
Stage of periodontal disease
Mild/moderate vs. none 3 0.69 (0.47, 1.00) 0.052 0.567 0.0%
Severe/edentulism vs. none 3 0.85 (0.58, 1.24) 0.393 0.104 44.6%
Abbreviations: NA, not available.
Table 4: Results of subgroup analyses of pooled relative risk (RR) and 95% confidence interval (CI).
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Analyses stratified by smoking status showed that PD 
was associated with risk of hematopoietic and lymphat-
ic cancers among never smokers (RR = 1.28; 95% CI 
= 1.07–1.54) but not among past (RR = 1.12; 95% CI 
= 0.83–1.52) or current smokers (RR = 1.25; 95% CI 
= 0.30–5.25). A gender-specific analysis showed that 
the association between PD and risk of hematopoietic 
and lymphatic cancers was not statistically significant 
in male and female population (summary RR = 1.12; 
95% CI = 0.98–1.28), and female population (pooled RR 
= 1.11; 95% CI = 0.95–1.30), respectively. Four studies 
were performed in America, one in Asia, and one in Eu-
rope. For subgroup analysis by geographic region, the 
significant association between PD and risk of hemato-
poietic and lymphatic cancers was observed among the 
American population (RR = 1.17; 95% CI = 1.05–1.30). 
Stratification analysis by ethnicity demonstrated no 
significant association between PD and risk of hema-
topoietic and lymphatic cancers in the white population 
or non-white population. Moreover, pooled estimates 
found no evidence of increased risk of hematopoietic 
and lymphatic cancers among individuals with mild/
moderate PD (RR = 0.69; 95% CI = 0.47–1.00) and se-
vere/edentulism PD (RR = 0.85; 95% CI = 0.58–1.24), 
respectively. 
-  Sensitivity analyses
In sensitivity analysis using the leave-one-out approach, 
the results showed that no individual study significantly 
altered the pooled RR for PD on hematopoietic and lym-
phatic cancers risk, with pooled RR varying from 1.12 
(95% CI, 1.01–1.24) to 1.20 (95% CI, 1.08–1.32), dem-
onstrating the meta-analysis results were robust (Figure 
not shown). 
-  Bias assessment
To examine the extent of publication bias for included 
studies, funnel plot and Egger regression analysis were 
conducted. The funnel plot on included studies showed 
a little asymmetry (Fig. 3). The Egger regression analy-
sis was not significant for publication bias across studies 
(P = 0.224).
Fig. 2: Forest plot for periodontal disease associated with hemato-
poietic and lymphatic cancers risk. The relative risk with 95% confi-
dence interval for each study is represented by the square and hori-
zontal line, respectively. The diamonds show the estimated pooled 
relative risk with corresponding 95% confidence interval.
Fig. 3: Funnel plot to assess publication bias. Each point indicates 
individual studies included in the meta-analysis.
Discussion
The results on the association between PD and the risk 
of hematopoietic and lymphatic cancer are less consis-
tent. No associations were detected in four of the six 
included studies (13,15,17,18), but two studies reported 
a higher risk of hematopoietic and lymphatic cancer 
among participants with PD (14,16). The qualitative 
synthesis results indicated that PD was significantly as-
sociated with increased risk of hematopoietic and lym-
phatic cancers, especially lymphatic cancers, which is 
in agreement with previous report (19).
The underlying mechanisms behind the potential as-
sociation are as follows: first, PD may increase cancer 
risk through the chronic release of inflammatory me-
diators or immune system dysregulation (29-32). Sec-
ond, PD may influence carcinogenesis via the increased 
exposure to carcinogenic nitrosamines (33). PD and 
poor dental hygiene were shown to enhance the forma-
tion of nitrosamines and oral bacteria in the oral cavity 
(34). Thus, anti-inflammation treatments for PD reduce 
markers of systemic inflammation and may decrease 
subsequent cancer risks. However, Hwang et al. found 
that anti-inflammation therapies of PD did not reduce 
the risk of hematopoietic and lymphatic cancers (35). 
Tooth loss is often the result of severe periodontitis. 
Moreover, tooth loss was found to be positively associ-
ated with risk of certain cancers such as head and neck, 
esophageal, and lung cancers (34). A dose-response 
meta-analysis revealed that each ten-tooth loss was as-
sociated with a 3% increment of risk of hematopoietic 
cancer (36). 
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Our meta-analysis has several potential limitations. 
First, although most included studies have adjusted for 
common covariates, other unmeasured confounding 
factors such as socioeconomic status, stress, along with 
genetics might affect the correlation between PD and 
risk of hematological cancers (37). Second, we noted 
that the sample size was small and the results had a wide 
confidence interval in two studies (13,15), which lim-
ited the power of analyses. Moderate heterogeneity was 
detected among some subgroups. These analyses were 
not sufficiently powered owing to the limited number 
of studies included in the stratified groups. Thus, the 
subgroup results should be interpreted with caution. Fi-
nally, subgroup analysis revealed increasing severity of 
periodontitis was not associated with risk of hematopoi-
etic and lymphatic cancers. Assessment methods of PD 
were heterogeneous in each study or the definitions for 
categories of PD severity varied between the included 
studies. Michaud et al., 2018 reported assessment of PD 
based on both level of attachment loss and pocket depth 
measurements (18), Mai et al., 2016 assessed PD sever-
ity using clinically measured alveolar crestal height 
(15), two studies used self-reported questionnaire for 
evaluating PD status (16,17), and two studies did not 
mention the procedures for assessment of PD (13,14), 
which might affect the heterogeneity and precision of 
our results. 
The strengths of our pooled analysis are as follows. 
First, the meta-analysis is the first to exclusively ex-
plore the correlation of PD with risk of hematopoietic 
and lymphatic cancers. Second, we found low hetero-
geneity across studies for overall estimate, there was 
no publication bias. Subgroup and sensitivity analyses 
revealed consistent results for the relation of PD with 
risk of hematopoietic and lymphatic cancers, which im-
ply the robustness and reliability of our findings. Third, 
most studies included in the meta-analysis were of high 
quality according to the predefined quality assessment 
criteria and controlled the major and common con-
founders (age, gender, body mass index, diabetes, and 
smoking). Four studies were prospective cohort stud-
ies (15-18), which minimized the recall and selection 
bias. Five studies have more than 15 years of follow-up 
(13,15-18). Sufficiently long follow-up (e.g. 5-10 years) 
is necessary because most human cancers have a long 
subclinical period (38,39). 
In summary, our pooled analysis indicates that peri-
odontitis is significantly associated with an increased 
risk of hematopoietic and lymphatic cancers, espe-
cially lymphatic cancers. Moreover, the associations 
are particularly strong in the population of never smok-
ers and the American population. However, additional 
prospective studies with a larger inclusion population, 
improved measurement and classification of PD, longer 
follow-up duration, and well-designed clinical models 
adjusted for the major and common confounders (e.g., 
age, gender, race, smoking status, body mass index, dia-
betes history) are warranted to confirm present findings. 
Additional research is expected to assess whether PD 
prevention and treatment can decrease the incidence of 
hematopoietic and lymphatic cancers. Findings of this 
meta-analysis highlight the importance of maintaining 
good oral health, which may led to a reduced risk of 
developing hematopoietic and lymphatic cancers.
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